• 作者：Santiago Palacios ; M. Jes¨²s Cancelo ; Camil Castelo-Branco ; Silvia Gonz¨¢lez ; Miguel ¨¢ngel Olalla
• 关键词：Atrofia vaginal ; Tratamiento ; Estró ; genos locales y sisté ; micos ; Hidratantes y lubricantes
• 刊名：Progresos de Obstetricia y Ginecolog¨ªa
• 出版年：2012
• 出版时间：October, 2012
• 年：2012
• 卷：55
• 期：8
• 页码：408-415
• 全文大小：364 K

Vaginal atrophy, caused by estrogen deficiency, leads to the development of symptoms that affect quality of life.

Treatment aims to restore the urogenital physiology and relieve symptoms. For symptoms such as vaginal dryness or dyspareunia associated with vaginal atrophy, the first line treatments are moisturizers (Evidence IA) and vaginal lubricants (Evidence IIB). If these treatments fail to provide sufficient improvement in symptoms or when the symptoms are moderate-to-intense, estrogen can be used. Estrogens are the most effective treatments. In patients with vaginal atrophy alone, the choice is local estrogen therapy (Evidence IA). In patients who also have vasomotor symptoms affecting quality of life, treatment consists of systemic hormone replacement therapy (Evidence IA). Low dose oestrogens are a first line pharmacological treatment for atrophic vaginitis.